Table 1 Characteristics of included patients by receipt of ultrasound enhancing agents in claims versus electronic medical records
From: Validation of administrative claims to identify ultrasound enhancing agent use
Baseline characteristics of individuals with UEAs identified in claims and EMR data | |||
|---|---|---|---|
Patient characteristic | Number (%) with UEA in Claims (N = 10,461) | Number (%) with UEA with in EMR (N = 12,853) | p-value |
Age group (y) | 0.02 | ||
0–17 | 0 (0.0%) | 4 (0.0%) | |
18–34 | 226 (2.2%) | 334 (2.6%) | |
35–44 | 515 (4.9%) | 669 (5.2%) | |
45–54 | 1181 (11.3%) | 1528 (11.9%) | |
55–64 | 2479 (23.7%) | 3085 (24.0%) | |
≥ 65 | 6060 (57.9%) | 7233 (56.3%) | |
Sex | < 0.001 | ||
Female | 4720 (45.1%) | 5836 (45.4%) | |
Male | 5741 (54.9%) | 6979 (54.3%) | |
Unknown | 0 (0.0%) | 38 (0.3%) | |
Any malignancy | 1676 (16.0%) | 2019 (15.7%) | 0.53 |
Metastatic malignancy | 464 (4.4%) | 547 (4.3%) | 0.52 |
Cerebrovascular disease | 1698 (16.2%) | 1990 (15.5%) | 0.12 |
Chronic pulmonary disease | 3169 (30.3%) | 3726 (29.0%) | 0.03 |
Congestive heart failure | 3476 (33.2%) | 4150 (32.3%) | 0.13 |
Connective tissue Diseases | 406 (3.9%) | 481 (3.7%) | 0.61 |
Dementia | 242 (2.3%) | 309 (2.4%) | 0.68 |
Diabetes | |||
With complications | 2054 (19.6%) | 2447 (19.0%) | 0.26 |
Without complications | 3778 (36.1%) | 4393 (34.2%) | 0.002 |
HIV/Aids | 78 (0.7%) | 112 (0.9%) | 0.32 |
Liver disease | |||
Mild | 1214 (11.6%) | 1490 (11.6%) | 0.99 |
Moderate or severe | 128 (1.2%) | 183 (1.4%) | 0.21 |
Myocardial infarction | 1565 (15.0%) | 1940 (15.1%) | 0.79 |
Paraplegia/hemiplegia | 167 (1.6%) | 232 (1.8%) | 0.24 |
Peptic ulcer disease | 207 (2.0%) | 245 (1.9%) | 0.73 |
Peripheral arterial disease | 2368 (22.6%) | 2825 (22.0%) | 0.24 |
Renal disease | 1872 (17.9%) | 2253 (17.5%) | 0.48 |
COVID-19 | 526 (5.0%) | 671 (5.2%) | 0.53 |